In contrast, a study of 22 heterogeneously expressed markers from stage II, III and IV patient melanomas, including CD271, ABCB5, [7] and CD133 [8] reported that all cells, whether marker-positive or -negative, had tumourigenic capacity when assayed in highly immune-deficient hosts. Here, PROM1 is linked to melanoma.